$13.43
0.52% yesterday
Nasdaq, Jun 13, 10:01 pm CET
ISIN
US03969K1088
Symbol
ARQT
Sector
Industry

Arcutis Biotherapeutics Inc Stock price

$13.43
-0.39 2.82% 1M
+0.74 5.83% 6M
-0.50 3.59% YTD
+4.09 43.79% 1Y
-16.03 54.41% 5Y
-8.37 38.39% 10Y
-8.37 38.39% 20Y
Nasdaq, Closing price Fri, Jun 13 2025
-0.07 0.52%
ISIN
US03969K1088
Symbol
ARQT
Sector
Industry

Key metrics

Market capitalization $1.60b
Enterprise Value $1.51b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 7.10
P/S ratio (TTM) P/S ratio 7.52
P/B ratio (TTM) P/B ratio 11.22
Revenue growth (TTM) Revenue growth 100.02%
Revenue (TTM) Revenue $212.82m
EBIT (operating result TTM) EBIT $-121.30m
Free Cash Flow (TTM) Free Cash Flow $-116.69m
Cash position $198.09m
EPS (TTM) EPS $-1.04
P/E forward negative
P/S forward 5.16
EV/Sales forward 4.86
Short interest 17.41%
Show more

Is Arcutis Biotherapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,847 stocks worldwide.

Arcutis Biotherapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Arcutis Biotherapeutics Inc forecast:

7x Buy
100%

Analyst Opinions

7 Analysts have issued a Arcutis Biotherapeutics Inc forecast:

Buy
100%

Financial data from Arcutis Biotherapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
213 213
100% 100%
100%
- Direct Costs 25 25
231% 231%
12%
188 188
90% 90%
88%
- Selling and Administrative Expenses 239 239
21% 21%
112%
- Research and Development Expense 71 71
28% 28%
33%
-116 -116
41% 41%
-54%
- Depreciation and Amortization 5.37 5.37
256% 256%
3%
EBIT (Operating Income) EBIT -121 -121
38% 38%
-57%
Net Profit -130 -130
40% 40%
-61%

In millions USD.

Don't miss a Thing! We will send you all news about Arcutis Biotherapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Arcutis Biotherapeutics Inc Stock News

Positive
Seeking Alpha
one day ago
Arcutis Biotherapeutics stands out in biotech for its impressive factor grades, which are rare in this sector. The recent FDA approval of ZORYVE Topical foam opens a significant revenue and profitability opportunity for Arcutis. FDA approval removes a major risk, allowing the company to commercialize and market its drug after years of costly R&D.
Neutral
GlobeNewsWire
4 days ago
Four-week Phase 2 study to evaluate investigational, once-daily ZORYVE .05% in infants as young as 3 months to less than 2 years with atopic dermatitis Atopic dermatitis impacts 9.6 million children in the United States; up to 60% of children with atopic dermatitis develop symptoms within their first year WESTLAKE VILLAGE, Calif., June 10, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. ...
Neutral
GlobeNewsWire
8 days ago
WESTLAKE VILLAGE, Calif., June 06, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.  (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 72,000 restricted stock units of Arcutis' common stock to nine newly hired employees. These awards were approved by the Compensation ...
More Arcutis Biotherapeutics Inc News

Company Profile

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical cream formulation of roflumilast that is in Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of ARQ-151 for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical small molecule inhibitor of janus kinase type 1 for hand eczema and other inflammatory dermatoses; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin to the postulated site of inflammation in alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was founded in 2016 and is headquartered in Westlake Village, California.

Head office United States
CEO Todd Watanabe
Employees 342
Founded 2016
Website arcutis.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today